foxo4-dri senolytic or senomorphic FOXO4-DRI: Human Trial Status, Cancer Research & Data Molecular modelling of the FOXO4-TP53
Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect FOXO4 DRI UK Senolytic Peptide Research Peptides Lab UK Senotherapy for chronic lung disease Pharmacological Reviews The FOXO4 peptide in a DRI conformation (D amino acids in a retro reversed sequence), henceforth named FOXO4 DRI, competes with FOXO4 for p53 binding in a dose dependent manner and doing so with higher affinity. Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9



